Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)

In the U.S., FDA approval establishes Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD) as the first immunotherapy combination approved for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin Lymphoma (cHL) With approval in the EU, Opdivo in combination with brentuximab vedotin is now the … [Read more…]

ImmunityBio Announces Approval in Macau SAR, China for ANKTIVA® in BCG-Unresponsive NMIBC with CIS ± Papillary Tumors

Macau SAR, China regulator grants approval for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in patients with BCG-unresponsive NMIBC with CIS ± papillary tumors Authorization follows a reliance-based review referencing prior FDA and EMA decisions First ANKTIVA authorization in Asia, supporting ongoing global expansion across 34 countries and territories CULVER CITY, Calif.–(BUSINESS WIRE)–ImmunityBio, Inc. (NASDAQ: IBRX), today announced … [Read more…]

Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting

– New, late-breaking 54-week data for povorcitinib in hidradenitis suppurativa (STOP-HS1 & STOP-HS2) to be highlighted – Featured abstracts for ruxolitinib cream (Opzelura®) and povorcitinib include multiple ePosters in atopic dermatitis, hidradenitis suppurativa and vitiligo WILMINGTON, Del.–(BUSINESS WIRE)–$INCY #AAD2026–Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will … [Read more…]

Qiagen Announces Form 20-F Annual Report Filing for 2025 Results

VENLO, the Netherlands–(BUSINESS WIRE)–$QGEN #QIAGEN–QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here. QIAGEN will … [Read more…]

The 15-20 National Hospital and GenSight Biologics Announce the First Treatments in the French Named Patient Early Access Program (AAC) for GS010/LUMEVOQ®

The first group of patients in the GS010 AAC program were treated at the 15-20 National Hospital in Paris on March 19. The REVISE dose-ranging study is proceeding according to the planned timeline. PARIS–(BUSINESS WIRE)–Regulatory News: The 15-20 National Hospital (l’Hôpital national des 15-20) in Paris and GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), … [Read more…]

Galderma Publishes Invitation and Agenda for Its 2026 Annual General Meeting

The Board of Directors proposes a dividend of 0.35 CHF per registered share Harry Kirsch proposed as new independent member of the Board of Directors Delphine Viguier-Hovasse and Samuel du Retail proposed as two non-independent board members from L’Oréal ZUG, Switzerland–(BUSINESS WIRE)–Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today published the invitation … [Read more…]

Phreesia and Sesame Workshop Win Point of Care Excellence Award for Best Unbranded Campaign

ALL-REMOTE COMPANY/WILMINGTON, Del.–(BUSINESS WIRE)–Phreesia, a leader in patient intake, outreach and activation, and Sesame Workshop, the global nonprofit behind Sesame Street, received the Point of Care Excellence Award for their pediatric health and wellness campaign. The award, announced at the Point of Care Marketing Association’s (POCMA) POC Now Summit on March 18, recognizes outstanding campaigns, … [Read more…]

Aptar’s Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA‑051 Nasal Spray

Use of Aptar Pharma’s UDS Powder system supports the development of a next‑generation, virus‑agnostic nasal spray being evaluated for its potential to help protect against symptomatic viral respiratory infections CRYSTAL LAKE, Ill,–(BUSINESS WIRE)–AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that its Unidose (UDS) … [Read more…]

QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention

New study supports QuantiFERON-TB Gold Plus use in immunocompromised and other high-risk populations in various settings Findings show QuantiFERON testing is cost-effective compared with tuberculin skin testing in people living with HIV CPD-accredited online QuantiFERON World TB Day program on March 24 convenes global experts to advance TB detection, prevention and high-impact scientific exchange GERMANTOWN, … [Read more…]

New Issue Brief from Rivera: PBM Reform Raises the Bar for Pharmacy Benefit Oversight but Does Not Replace It

Rivera examines why federal and state pharmacy benefit reforms demand continuous, claim-level monitoring, not just new rules COLUMBUS, Ohio–(BUSINESS WIRE)–Rivera, an independent pharmacy payment integrity company, published a new issue brief examining why the current wave of PBM reform raises the bar for pharmacy benefit oversight without replacing the need for it. Recent federal and … [Read more…]